Investing to become financially independent
Investing to become financially independent
An analysis of Clorox's remarkable performance following Carl Icahn's investment, with a focus on its dividend strategy and stability in times of crisis. The portfolio shows marked improvement with volatility under control, thanks in particular to strategic investments such as Coca-Cola.
Clorox (NYSE:CLX), +7.56% Friday Read More »
Find out why Enbridge, the Canadian oil and gas transmission giant, has been offering attractive long-term yields and growing dividends for 16 years. Despite its attractive dollar diversification benefits and low volatility, the high payout ratio of 67.30% currently prompts caution.
Enbridge (Toronto:ENB.TO) Read More »
The portfolio is showing encouraging signs thanks to the simultaneous progress of the dollar and the market, despite remaining in the red. Strategic adjustments to the algorithm have been made to better manage currency risk, with a particular focus on stocks offering good resistance to dollar fluctuations.
Slightly better... Read More »
The portfolio's disappointing performance has prompted us to refocus on our investment strategy of regular dividends, while maintaining a long-term view. In the face of current market volatility and a weak dollar, it is crucial to maintain a realistic and disciplined approach, staying true to our objective of investing in quality stocks.
A dark week for defensives and the dollar Read More »
Discover our detailed analysis of Sanofi Aventis, the world's 5th largest pharmaceutical group, and its attractiveness as a dividend stock. The stock, trading at attractive prices with a yield of 5.16% in 2011, has attractive characteristics despite its relative youth compared to other major players in the sector.
Sanofi Aventis (PA:SAN) Read More »
The portfolio suffered a drop in profitability to -4.74% following the fall of CenturyLink, but maintained a solid performance in euros with a Sharpe ratio higher than the benchmark indices. Dividends continue to rise, and new stocks such as Novartis and Roche are now being monitored to diversify the portfolio.
Released by CenturyLink... Read More »
The merger of Ciba-Geigy and Sandoz in 1996 gave rise to Novartis, now the world's 3rd largest pharmaceutical group. Despite its relative youth, the Basel-based company presents an attractive profile for investors, with a dividend yield of 3% and steadily increasing payouts.
Novartis (VTX:NOVN) Read More »
Discover our analysis of our stock market performance, which is now outperforming expectations thanks to the dollar's leverage effect, with a significant increase compared with the end of 2010. Despite remaining in negative territory at -4.58%, this positive correction in the equity market and the dollar offers encouraging prospects for 2011.
Gain with leverage Read More »